+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

New onset diabetes and impaired fasting glucose after liver transplant: risk analysis and the impact of tacrolimus dose



New onset diabetes and impaired fasting glucose after liver transplant: risk analysis and the impact of tacrolimus dose



Experimental and Clinical Transplantation 12(1): 46-51



New onset diabetes mellitus after transplant is one of the major metabolic complications after liver transplant. Development of impaired fasting glucose after liver transplant is thought to be associated with increased risk of cardiovascular mortality and has not been well studied before. The aim of this study was to evaluate incidence and risk factors of new onset diabetes mellitus after transplant and impaired fasting glucose in liver transplant patients. In a cross-sectional study, all adult patients (aged≥18 years) who were transplanted because of chronic liver diseases from June 2002 to September 2010 at Shiraz Liver Transplant Center were evaluated for developing diabetes and impaired fasting glucose. Totally, 86 patients (18.81%) were found to have diabetes after liver transplant. Forty patients (27 men and 13 women; 8.75%) developed new onset diabetes mellitus after transplant and 36 patients (7.87%) developed impaired fasting glucose after liver transplant. The mean age of patients with new onset diabetes mellitus after transplant was higher than that of nondiabetic patients (P = .001). Mean fasting plasma glucose before liver transplant was significantly higher in diabetic patients compared with nondiabetic patients (P = .002) (5.20±0.93 mmol/L vs 4.44±0.56 mmol/L) (93.86±16.80 mg/dL vs 80±10.14 mg/dL). Patients with new onset diabetes mellitus after transplant received higher doses of tacrolimus as immunosuppressive medication than nondiabetic patients (P = .001). Fasting plasma glucose before transplant can predict development of new onset diabetes mellitus after transplant. Age and tacrolimus dosage are independent risk factors for new onset diabetes mellitus after transplant in our patients.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 054610935

Download citation: RISBibTeXText

PMID: 23902591


Related references

Differences in the risk of fatty liver for onset of impaired fasting glucose according to baseline plasma glucose levels. Journal of Gastroenterology 52(2): 237-244, 2017

Impact of the waist circumference change on new onset of diabetes in the population with impaired fasting glucose. Zhonghua Yu Fang Yi Xue Za Zhi 47(7): 622-626, 2013

Comparison of the 1997 and 2003 American Diabetes Association classification of impaired fasting glucose: impact on prevalence of impaired fasting glucose, coronary heart disease risk factors, and coronary heart disease in a community-based medical practice. Journal of the American College of Cardiology 48(2): 293-297, 2006

Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Annals of Epidemiology 14(9): 686-695, 2004

Evaluation of the safety, efficacy and tolerability of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset Type 2 diabetes. Diabetes & Metabolism 29(Hors serie 2): 4S230, 2003

A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes. Experimental and Clinical Endocrinology and Diabetes 116(5): 282-288, 2008

Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 116(2): 151-157, 2007

Prevalence of impaired fasting glucose, impaired glucose tolerance and newly-diagnosed diabetes in subjects at risk of developing type 2 diabetes. 2007

Evaluation of the Finnish Diabetes Risk Score as a screening tool for impaired fasting glucose, impaired glucose tolerance and undetected diabetes. Diabetes Research and Clinical Practice 92(1): 46-52, 2011

Analysis of common type 2 diabetes mellitus genetic risk factors in new-onset diabetes after transplantation in kidney transplant patients medicated with tacrolimus. European Journal of Clinical Pharmacology 68(12): 1587-1594, 2012

Diagnostic Accuracies of Glycated Hemoglobin, Fructosamine, and Homeostasis Model Assessment of Insulin Resistance in Predicting Impaired Fasting Glucose, Impaired Glucose Tolerance, or New Onset Diabetes After Transplantation. Transplantation Journal 100(7): 1571-1579, 2016

Diagnostic Accuracies of Glycated Hemoglobin, Fructosamine, and Homeostasis Model Assessment of Insulin Resistance in Predicting Impaired Fasting Glucose, Impaired Glucose Tolerance, or New Onset Diabetes After Transplantation. Transplantation 100(7): 1571-1579, 2016

Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Yearbook of Cardiology 2008: 308-310, 2008

Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet 370(9588): 667-675, 2007

Fasting plasma glucose, not impaired fasting glucose, predicts 4 years diabetes incidence among high-risk Spanish individuals. Diabetes 50(Suppl. 2): A201-A202, 2001